Global small molecule API market will reach $360.0 billion by 2032, growing by 7.0% annually over 2022-2032, driven by the increasing incidences of diseases, the development of high-potency small molecule APIs, patents expiry of the top-selling pharmaceuticals, the increasing technological developments in manufacturing sector, and a surging healthcare expenditure.
Highlighted with 119 tables and 84 figures, this 187-page report “Global Small Molecule API Market 2022-2032 by Source (Synthetic, Semi-synthetic, Natural), Product Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Region: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire global small molecule API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global small molecule API market in every aspect of the classification from perspectives of Source, Product Type, Therapeutic Area, Application, Manufacturer Type, and Region.
Based on Source, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Synthetic API
o Branded Synthetic API
o Generic Synthetic API
• Semi-synthetic API
• Natural Origin
Based on Product Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Standard API
• High Potency API (HPAPI)
o Branded HPAPI
o Generic HPAPI
By Therapeutic Area, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Metabolic Diseases
• Other Therapeutic Areas
By Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Clinical Use
• Commercial Use
By Manufacturer Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pharmaceutical Companies
• CMOs
Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
For each region and country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of all regional markets by country and the breakdown of each national market by Product Type, Therapeutic Area, and Manufacturer Type over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Aurobindo Pharma Ltd.
Cambrex Corporation
Catalent Inc.
Dr. Reddy’s Laboratories
GlaxoSmithKline plc
Lonza Group
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Wuxi AppTec Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
Request for Sample & brochure@https://www.supplydemandmarketresearch.com/home/contact/1703167?ref=Sample-and-Brochure&toccode=SDMRHE1703167
The report provides competitive landscape provides detailed and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2023-2030. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2023-2030. Details included are company description, major business, product introduction, recent developments, product range.
Request for Discount @ https://www.supplydemandmarketresearch.com/home/contact/1703167?ref=Discount&toccode=SDMRHE1703167
Key questions answered in this report:
What will the market size be in 2030 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Canada Office:
302-20 Mississauga Valley Blvd, Mississauga, L5A 3S1, Toronto
Email- info@supplydemandmarketresearch.com
Website- www.supplydemandmarketresearch.com
Tel-+1-276-477-5910
Leave a reply